Skip to Content

Dexrazoxane Injection

Last Updated: May 7, 2020
Status: Current

Products Affected - Description
    • Zinecard injection, Pfizer, 500 mg, vial, 1 count, NDC 00013-8727-89
    • Dexrazoxane injection, Hikma, 250 mg, vial, 1 count, NDC 00143-9247-01
Reason for the Shortage
    • Cumberland Pharmaceuticals relaunched Totect in late-July 2017.
    • Fosun Pharma has dexrazoxane available.
    • Hikma did not provide a reason for the shortage.
    • Mylan Institutional has dexrazoxane available.
    • Pfizer states manufacturing delay as the reason for the shortage.
Available Products
    • Totect kit, Cumberland Pharmaceuticals, 500 mg, vial, (only for extravasation injuries) 1 count, NDC 66220-0110-01
    • Zinecard injection, Pfizer, 250 mg, vial, 1 count, NDC 00013-8717-62
    • Dexrazoxane injection, Fosun Pharma, 500 mg, vial, 1 count, NDC 72266-0101-01
    • Dexrazoxane injection, Hikma, 500 mg, vial, 1 count, NDC 00143-9248-01
    • Dexrazoxane injection, Mylan Institutional, 250 mg, vial, 1 count, NDC 67457-0207-25
    • Dexrazoxane injection, Mylan Institutional, 500 mg, vial, 1 count, NDC 67457-0208-50

Estimated Resupply Dates

    • Hikma has dexrazoxane 250 mg vials on back order and the company estimates a release date of mid-May 2020.
    • Pfizer has Zinecard 500 mg vials on back order and the company estimates a release date of August 2020.

Updated

Updated May 7, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 30, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide